Name | Rio Grande Hospital |
---|---|
Type | Critical Access Hospital |
Location | 310 County Rd 14, Del Norte, Colorado |
Ownership | Voluntary non-profit - Private |
Emergency Services | Yes |
Medicare ID (CCN) | 061301 |
NPI Number | 1396783981 |
Organization Name | VALLEY CITIZENS' FOUNDATION FOR HEALTH CARE INC |
Doing Business As | RIO GRANDE HOSPITAL |
Address | 310 County Road 14, Del Norte, CO 81132 |
Hospital Type | General Acute Care Hospital - Critical Access |
Phone Number | 719-657-2510 |
News Archive
Researchers from The University of Texas at Austin will participate in a $3 million, five-year grant from the National Institutes of Health (NIH) to fight influenza and other diseases by creating models that simulate the complex interplay between human behavior and the spread of disease.
ADVANCELL, an emerging biopharmaceutical company, today announced positive results from a clinical study conducted with Acadra (Acadesine) in Chronic Lymphocytic Leukemia patients resistant to current therapies. The company also announced promising non-clinical results in Multiple Myeloma (MM), Mantle Cell Lymphoma (MCL) and other lymphoproliferative disorders. Synergism of Acadra in combination with current treatment in these indications has been demonstrated.
Embrella Cardiovascular, Inc., a privately held company announced that it has completed its first clinical case using the Embrella Embolic Deflector™. The company has developed a novel technology designed to make less invasive cardiovascular procedures safer for patients by decreasing the risk of emboli traveling to the brain.
The contract with Verizon Communications Inc.'s Terremark subsidiary, which hosts healthcare.gov, had been set to expire March 30, the day before the end of open enrollment.
Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for chronic fibrotic and metabolic diseases, today announced the signing of a cooperative research and development agreement (CRADA) with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health to conduct a double blind, multi-center, study to evaluate the effects of obeticholic acid in patients with nonalcoholic steatohepatitis (NASH).
› Verified 8 days ago
Able to receive lab results electronically | Not Available |
Able to track patients' lab results, tests, and referrals electronically between visits | Not Available |
News Archive
Researchers from The University of Texas at Austin will participate in a $3 million, five-year grant from the National Institutes of Health (NIH) to fight influenza and other diseases by creating models that simulate the complex interplay between human behavior and the spread of disease.
ADVANCELL, an emerging biopharmaceutical company, today announced positive results from a clinical study conducted with Acadra (Acadesine) in Chronic Lymphocytic Leukemia patients resistant to current therapies. The company also announced promising non-clinical results in Multiple Myeloma (MM), Mantle Cell Lymphoma (MCL) and other lymphoproliferative disorders. Synergism of Acadra in combination with current treatment in these indications has been demonstrated.
Embrella Cardiovascular, Inc., a privately held company announced that it has completed its first clinical case using the Embrella Embolic Deflector™. The company has developed a novel technology designed to make less invasive cardiovascular procedures safer for patients by decreasing the risk of emboli traveling to the brain.
The contract with Verizon Communications Inc.'s Terremark subsidiary, which hosts healthcare.gov, had been set to expire March 30, the day before the end of open enrollment.
Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for chronic fibrotic and metabolic diseases, today announced the signing of a cooperative research and development agreement (CRADA) with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health to conduct a double blind, multi-center, study to evaluate the effects of obeticholic acid in patients with nonalcoholic steatohepatitis (NASH).
› Verified 8 days ago
Rio Grande Hospital Critical Access Hospital Location: 310 County Rd 14, Del Norte, Colorado 81132 Phone: (719) 657-2510 |